Hyperion DeFi (NASDAQ:HYPD) Lowered to “Strong Sell” Rating by Zacks Research

Hyperion DeFi (NASDAQ:HYPD) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday,Zacks.com reports.

HYPD has been the topic of several other research reports. Cantor Fitzgerald upped their price target on Hyperion DeFi from $6.60 to $7.10 and gave the stock an “overweight” rating in a report on Thursday. Chardan Capital reiterated a “buy” rating and issued a $7.30 price objective on shares of Hyperion DeFi in a research note on Tuesday. Finally, Weiss Ratings raised Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.20.

Hyperion DeFi Stock Performance

NASDAQ:HYPD opened at $2.83 on Wednesday. Hyperion DeFi has a 52 week low of $2.34 and a 52 week high of $15.00. The company has a fifty day simple moving average of $2.91 and a two-hundred day simple moving average of $3.36. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.12. The company has a market cap of $42.90 million, a price-to-earnings ratio of -0.43 and a beta of 2.53.

Hyperion DeFi (NASDAQ:HYPD) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.92 earnings per share (EPS) for the quarter. The business had revenue of $0.36 million for the quarter. Hyperion DeFi had a negative return on equity of 13.93% and a net margin of 416.56%. As a group, equities analysts anticipate that Hyperion DeFi will post 1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Hyperion DeFi

In other news, insider Hyunsu Jung acquired 7,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was acquired at an average cost of $3.70 per share, with a total value of $25,900.00. Following the transaction, the insider owned 1,384,676 shares in the company, valued at approximately $5,123,301.20. This trade represents a 0.51% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Hyperion DeFi

Large investors have recently bought and sold shares of the business. Redwood Wealth Management Group LLC raised its stake in Hyperion DeFi by 2.1% in the first quarter. Redwood Wealth Management Group LLC now owns 183,273 shares of the company’s stock valued at $632,000 after buying an additional 3,690 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Hyperion DeFi during the 4th quarter worth about $73,000. State Street Corp acquired a new position in shares of Hyperion DeFi during the 4th quarter worth about $92,000. Jane Street Group LLC acquired a new position in shares of Hyperion DeFi during the 4th quarter worth about $493,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Hyperion DeFi in the 4th quarter valued at about $663,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.